Mapping Cellular Stress Biology to Tackle Undruggable Targets
About this episode
Yerem Yeghiazarians discusses how Soley Therapeutics uses AI to tackle undruggable targets in drug development.
Cells continuously sense their environment and in response to stressors, adapt, recover, or die. Soley Therapeutics uses its AI platform to capture thousands of intracellular features and map how cells sense, interpret, and respond to stress. The approach gives Soley the ability to pursue previously undruggable targets. It has generated more than 10 novel oncology programs in less than two years and advanced two first‑in‑class experimental small molecule therapies toward the clinic. Yerem Yeghiazarians, co-founder and CEO of Soley, discusses the science behind the company’s first-in-class lead candidate, the applicability of Soley’s platform to a broad set of diseases, and the capital efficiency of the company’s approach to drug development.
More episodes of The Bio Report
- Rewriting the Rules of Antibody Drug Design
- Turning Abandoned Drugs into Breakthroughs
- Targeting Cancer Survival Genes in Solid Tumors
Explore listener stats, chart rankings, contacts and more on the The Bio Report podcast page.